Vimarsana
Biggest News Aggregation in the World

Page 5 - Med Sci News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Med Sci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Med Sci Today - Breaking & Trending Today

Frontiers | Suspension of Care for Patients With Spasticity During COVID-19 Pandemic: Ethical and Medico-Legal Point of View Starting From an Italian Study - Vimarsana News

Frontiers | Suspension of Care for Patients With Spasticity During COVID-19 Pandemic: Ethical and Medico-Legal Point of View Starting From an Italian Study

The COVID-19 pandemic has revolutionized the habits of entire communities, having even more profound negative effects on assistance for the chronically ill. The sudden demand for extraordinary resources caught all worldwide countries unprepared, highlighting shortages in provision of care services. This applies to all patients, affected by COVID-19 or not, as many need continuing access to chronic diseases treatments. Almost all of the energy available has been directed toward care of COVID-19 patients, and almost nothing has been done to continue therapy for patients with spasticity. This stu...

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection - Vimarsana News

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection

1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, Regeneron, ZMapp and MAb114) have been evaluated in a RCT, the Pamoja Tulinde Maisha (PALM) study. Tw...